Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate and Duloxetine for Cocaine Use Disorder
NCT03519022Phase 1Completed
- Start
- Jun 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet and duloxetine in cocaine use disorder (CUD) (2 arms). Primary endpoints: Reinforcing Effects of Cocaine Following Placebo Maintenance, Reinforcing Effects of Cocaine Following Duloxetine Maintenance and 2 more. Started Jun 2018; status: completed.
02
Drugs
methylphenidate hydrochloride extended-release chewable tabletduloxetine
03
Conditions
cocaine use disorder (CUD)
Beyond the preview
Go deeper on NCT03519022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03519022.